- BMO Capital Markets initiated the coverage on Precision BioSciences Inc DTIL with an Outperform rating and a price target of $7.
- The analyst said the thesis is based on:
- The company's proprietary gene-editing platform, whose mechanism is differentiated in a CRISPR-dominated space, offers several advantages.
- A diversified pipeline.
- Asymmetric risk/reward skewed to the upside.
- The analyst says that Precision's mechanism of action appears safer than competitors. Its smaller size allows for delivery with viral and non-viral systems.
- Also Read: Precision BioSciences Highlights Interim Data From Allogeneic CAR T Programs In Blood Cancer Patients.
- Preclinical data demonstrate a favorable benefit/risk profile.
- The company also entered into a collaboration agreement with Eli Lilly And Co LLY, further validating the platform's potential.
- BMO believes that Precision's platform can deliver competitive clinical data.
- The analyst said, "Precision's valuation currently does not account for the in vivo platform, derisking the platform in the clinic via clean safety and sufficient efficacy in 2023 or beyond can drive more than 100% upside for the stock."
- Price Action: DTIL shares are up 10.90% at $1.28 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
